Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
44.5M
-
Number of holders
-
63
-
Total 13F shares, excl. options
-
8.04M
-
Shares change
-
+803K
-
Total reported value, excl. options
-
$59.4M
-
Value change
-
+$2.23M
-
Number of buys
-
37
-
Number of sells
-
-16
-
Price
-
$7.38
Significant Holders of Outlook Therapeutics, Inc. - Common Stock, $0.001 par value per share (OTLK) as of Q2 2024
71 filings reported holding OTLK - Outlook Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q2 2024.
Outlook Therapeutics, Inc. - Common Stock, $0.001 par value per share (OTLK) has 63 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.04M shares
of 44.5M outstanding shares and own 18.08% of the company stock.
Largest 10 shareholders include GREAT POINT PARTNERS LLC (1.7M shares), TANG CAPITAL MANAGEMENT LLC (1.62M shares), BlackRock Inc. (663K shares), SPHERA FUNDS MANAGEMENT LTD. (571K shares), VANGUARD GROUP INC (548K shares), Altium Capital Management LP (502K shares), Caligan Partners LP (500K shares), Schonfeld Strategic Advisors LLC (286K shares), BOOTHBAY FUND MANAGEMENT, LLC (250K shares), and Velan Capital Investment Management LP (247K shares).
This table shows the top 63 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.